Achieving Vascular Integrity Through Novel Therapeutics That Target the Angiopoietin/Tie Pathway

Author(s)/Faculty: Karl G. Csaky, MD, PhD; Anat Loewenstein, MD
Release Date: 9/30/2022Expiration Date: 9/29/2023
Credit Type: CMENumber of Credits: 1
Content Type: MonographProvider:
Lack of response or suboptimal response in a proportion of patients treated with intravitreal anti-vascular endothelial growth factor (VEGF) therapies have defined a need to identify alternate therapeutic targets for the management of retinal and choroidal vascular diseases. One such target is the angiopoietin/Tie2 pathway, which has been shown to be involved in increased vascular permeability and abnormal angiogenesis within the eye. Recently, the FDA approved the first agent for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) that inhibits both the angiopoietin-2 (Ang-2) and VEGF-A pathways, providing the potential for enhanced visual acuity outcomes when optimally integrated into management paradigms. In this eMonograph, experts in the field review the angiopoietin/Tie2 pathway as well as its role in inflammation, homeostasis, and vascular development and maintenance, and assess the latest safety and efficacy data for injectable therapies that act on the angiopoietin/Tie2 pathway to improve visual outcomes in patients with retinal and choroidal vascular diseases.